Therapeutic advances in spinal muscular atrophy: a review of clinical, safety, and economic considerations

Andrej Belančić, Elvira Meni Maria Gkrinia, Yun Wah Lam, Dinko Vitezić · 2026

Read Therapeutic advances in spinal muscular atrophy: a review of clinical, safety, and economic considerations by Andrej Belančić, Elvira Meni Maria Gkrinia, Yun Wah Lam, Dinko Vitezić (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13617402.txt.

Description

Andrej Belančić and co-authors checked the transformed treatment landscape of spinal muscular atrophy in 2026. The disease is a genetic mess in which a missing survival motor neuron protein, caused by mutations in the SMN1 gene, destroys the motor neurons of the spinal cord. Within a few years, three approved disease-modifying treatments have changed its course: an injected antisense drug, a one-time gene treatment, and a daily oral drug.

The review summarizes trial efficacy and real-world effectiveness for all three, finding major gains in survival, motor milestones, and quality of life, strongest when treatment starts early. Safety data from trials and post-marketing surveillance show manageable side effects. The harder chapter is economics: prices are high and cost-effectiveness strains standard thresholds, though context matters. A section surveys the workflow of next-generation treatments aiming at the missing protein and independent targets such as muscle itself.

Catalog record

CREATORAndrej Belančić, Elvira Meni Maria Gkrinia, Yun Wah Lam, Dinko Vitezić
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE58 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC13617402

Browse the full library · About the Tower of Babel